IntrinsicIntrinsic
OverviewFinancialsChartBusiness SummaryFilingsOwnershipValuation

SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Pharmaceutical Preparations

Latest Price
$41.28
TTM P/E
--
Normalized P/E
189.36
Div Yield
--
Book Value
17.82
P/B Ratio
2.32

Valuation metrics

adjust assumptions →
Norm. op. income: $84M (median of 6yr)
Tax rate: 25%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$19.66
52% downside
Base FCF: $138M (median of recent 4yr)
Growth: -4%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$30.09
27% downside

Institutional Ownership

100.0% held by institutions
InstitutionSharesValueOwnership %ChangeFiling Date
BlackRock, Inc.9.35M$434.0M16.08%+552.8K2026-06-30
MILLENNIUM MANAGEMENT LLC3.85M$179.0M6.62%+537.2K2026-06-30
VANGUARD PORTFOLIO MANAGEMENT LLC3.31M$153.0M5.68%+66.7K2026-06-30
ARMISTICE CAPITAL, LLC2.65M$123.0M4.55%+750.9K2026-06-30
VANGUARD CAPITAL MANAGEMENT LLC2.52M$117.0M4.33%+49.5K2026-06-30
STATE STREET CORP2.46M$114.0M4.23%+171.7K2026-06-30
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.2.38M$110.0M4.09%+341.1K2026-06-30
DIMENSIONAL FUND ADVISORS LP2.08M$96.0M3.57%-228.9K2026-06-30
GEODE CAPITAL MANAGEMENT, LLC1.57M$73.0M2.70%-53.4K2026-06-30
Stephens Investment Management Group LLC1.49M$69.0M2.55%+134.5K2026-06-30
View all institutional holders →